Rafferty Asset Management
NKTR icon

Rafferty Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Rafferty Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-929
Closed -$31.5K – 1159
2022
Q4 		$31.5K Sell
929
-1,312
-59% -$63.5K ﹤0.01% 1117
2022
Q3 		$108K Sell
2,241
-2,519
-53% -$150K ﹤0.01% 1121
2022
Q2 		$271K Buy
4,760
+3,202
+206% +$202K ﹤0.01% 944
2022
Q1 		$126K Sell
1,558
-58
-4% -$8.58K ﹤0.01% 1161
2021
Q4 		$327K Buy
1,616
+512
+46% +$111K ﹤0.01% 1136
2021
Q3 		$298K Buy
1,104
+371
+51% +$89.2K ﹤0.01% 1129
2021
Q2 		$189K Buy
+733
New +$203K ﹤0.01% 1233
2021
Q1 		– Sell
-1,113
Closed -$284K – 1168
2020
Q4 		$284K Buy
+1,113
New +$288K ﹤0.01% 835
2020
Q3 		– Sell
-1,222
Closed -$424K – 1015
2020
Q2 		$424K Buy
+1,222
New +$381K 0.01% 748
2020
Q1 		– Sell
-1,277
Closed -$413K – 740
2019
Q4 		$413K Sell
1,277
-418
-25% -$121K 0.01% 721
2019
Q3 		$463K Buy
+1,695
New +$622K 0.01% 675

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rafferty Asset Management's NKTR Position: Q1 2023 in Review

Rafferty Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 929 shares — an estimated $31.5K sold.

Rafferty Asset Management first reported a position in NKTR in Q3 2019 and held it in 11 quarters. The position peaked at $463K in Q3 2019. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • Rafferty Asset Management reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 929 Nektar Therapeutics shares in Q1 2023, an estimated $31.5K.
  • Rafferty Asset Management first reported a position in Nektar Therapeutics in Q3 2019 and held it in 11 quarters.
  • Rafferty Asset Management's Nektar Therapeutics position peaked at $463K in Q3 2019.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.